Onyx Scientific clinches cancer research contract

Cancer Research UK the nation’s leading cancer charity has awarded Onyx Scientific, an active pharmaceutical ingredient (API) manufacturer, a contract to develop the chemistry and perform the GMP synthesis of the API for use in a Phase 1 clinical trial.

Dr Nigel Westwood, drug supply manager at Cancer Research UK, said: “Having had a very positive experience of using Onyx Scientific’s process development and GMP manufacturing services in the past, they seemed like a strong candidate for this important project.

“Despite the fact that Cancer Research UK had to change suppliers at such a critical stage, Onyx Scientific still expect to bring the project in on time and on budget. Given their expertise in chemistry and ability to deliver, we believe they are perfect fit for the project,” added Dr Westwood.

Onyx Scientific provides outsourced facilities and expertise to help pharmaceutical and biotech companies accelerate drug candidates from discovery, through development, into Phase I/II GMP API manufacturing. The Cancer Research UK project is one of the biggest projects in the firm’s history and is expected to take around seven months to complete.